WT1 and acute myeloid leukemia: It was shown that the absence of the BCL2 expression characterized a subgroup of AML patients with distinct molecular and clinical characteristics, including low BM blast percentage, low WT1 expression, underrepresentation of FLT3 mutations, positive response to chemotherapy, and better OS [107].